Quantum BioPharma receives Health Canada approval for Qlarity, enhancing energy and cognitive performance, now available in Canada.
Quiver AI Summary
Quantum BioPharma Ltd. announced that Health Canada has granted a Product License for its natural health product, Qlarity, allowing the company to sell it in Canada. Qlarity is also marketed in the U.S. as unbuzzd™, a dietary supplement. The product is designed to boost energy production, support electrolyte balance, enhance physical energy and motor performance, reduce fatigue, and improve mental alertness and cognitive performance. CEO Zeeshan Saeed emphasized the significance of this license in advancing Quantum BioPharma's mission, while Professor Lakshmi P. Kotra expressed enthusiasm for the product's launch in Canada. Quantum BioPharma, which focuses on treatments for neurodegenerative and metabolic disorders, retains ownership of a significant stake in the company producing unbuzzd™ and maintains the rights to develop related pharmaceutical products.
Potential Positives
- Health Canada granted a Product License for Qlarity, allowing Quantum BioPharma to sell the product in Canada, which expands its market reach.
- The approval signifies a milestone in the company's mission to introduce innovative health products, enhancing its portfolio in the biopharmaceutical sector.
- Qlarity's benefits, including support for energy production, metabolism, and cognitive performance, position it as a valuable addition to the health product market.
- The company retains ownership of a significant stake in Unbuzzd Wellness Inc., along with potential ongoing royalty payments that could contribute to future revenue.
Potential Negatives
- Health Canada’s product license may imply that Qlarity's benefits are not sufficiently proven, as it allows for claims that might not be strongly substantiated by clinical data.
- The press release mentions the licensing of Qlarity, yet provides limited information on the actual market competition, which could imply vulnerability in a crowded market for natural health products.
- The transition from royalty payments of 7% to 3% after reaching $250 million in sales could indicate a potential revenue downturn for the company in the long term, potentially impacting future earnings projections.
FAQ
What is Qlarity and its uses?
Qlarity is a natural health product approved by Health Canada, helping with energy production, metabolism, and cognitive performance.
How can I buy Qlarity in Canada?
Qlarity is now available for sale in Canada following its Product License approval from Health Canada.
What is the connection between unbuzzd™ and Qlarity?
Qlarity is licensed as a dietary supplement in the U.S. under the brand name unbuzzd™.
What does Quantum BioPharma specialize in?
Quantum BioPharma focuses on innovative solutions for neurodegenerative and metabolic disorders, including therapies for alcohol misuse.
What can we expect from Quantum BioPharma's future?
The company aims to introduce more innovative products like Qlarity and advance research in therapeutics for serious health conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd™ ( unbuzzd.com ). This Product License from Health Canada permits Quantum to sell Qlarity in Canada.
Health Canada’s product license permits the following recommended uses of Qlarity, among others: helps in energy production and metabolism; helps to maintain/support normal electrolyte balance; helps (temporarily) to enhance (physical) energy and motor performance, reduce fatigue, promote endurance, promote mental alertness, and enhance cognitive performance.
“This is a milestone in Quantum BioPharma’s mission to bring innovative products to the market”, said Mr. Zeeshan Saeed, CEO of Quantum BioPharma. “We can now sell Qlarity to the Canadian market, leveraging its significant potential to improve consumer well-being.”
“I am delighted that the Natural Health Products Directorate at Health Canada has provided a Product License for Qlarity”, said Professor Lakshmi P. Kotra, a board director at Quantum BioPharma, a professor of medicinal chemistry at University of Toronto, and a senior scientist at the Krembil Research Institute, University Health Network. “I look forward to the launch of Qlarity in Canada, offering a solution to support energy, metabolism, mental alertness and cognitive performance”.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at www.unbuzzd.com . The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
For more information visit www.quantumbiopharma.com .
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email:
[email protected]
Telephone: (833) 571-1811
Investor Relations
Investor Relations:
[email protected]
General Inquiries:
[email protected]
